FDA Fast Tracks IDP-023 for Non-Hodgkin Lymphoma and Myeloma
The natural killer cell therapy IDP-023 is being studied in a phase 1 trial for the treatment of patients with non-Hodgkin lymphoma and multiple myeloma.
Advancing Myeloma Treatment With Blood-Based MRD Testing
In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.
FDA Revokes Melphalan Flufenamide Approval, Citing Efficacy/Safety Concerns
Approval for melphalan flufenamide has been withdrawn by the FDA due to the failure of its confirmatory trial to demonstrate its clinical benefit and the lack of evidence supporting its safety and effectiveness.
Ciltacabtagene Autoleucel Produces Deep, Durable Responses in Multiple Myeloma
In early lines of therapy for relapsed/refractory multiple myeloma, patients receiving cilta-cel demonstrated deep and enduring responses, with overall response rates of 95% and 100% in 2 cohorts.
Utilization Challenges Hold Back the Adoption of Bispecific Therapies
Bispecific antibodies are a powerful class of therapy that offer an alternative or complement to CAR T-cell therapies, but there are similar challenges to implementing them in clinical practice. In live events, experts discussed their experience setting up standard operating procedures in their cancer centers.
Linvoseltamab Earns FDA Priority Review for Multiple Myeloma
Linvoseltamab shows promise for patients with heavily pretreated multiple myeloma, achieving a 71% overall response rate in a phase 1/2 trial.
2 Commerce Drive Cranbury, NJ 08512